We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

AI-Enhanced Platform Detects Cardiac Amyloidosis by Assessing Single Echocardiogram

By MedImaging International staff writers
Posted on 27 Apr 2023
Print article
Image: The EchoGo Amyloidosis platform has received FDA breakthrough device designation (Photo courtesy of Ultromics)
Image: The EchoGo Amyloidosis platform has received FDA breakthrough device designation (Photo courtesy of Ultromics)

Cardiac amyloidosis, a condition resulting from abnormal protein deposits in heart tissue, is a diverse disease that can be challenging to diagnose, often necessitating specialized expertise and testing. The disease is categorized based on the specific protein involved, with the primary subtypes being transthyretin amyloidosis (ATTR cardiac amyloidosis), caused by the misfolding of the transthyretin protein, and a less common form called light chain amyloidosis (AL cardiac amyloidosis), caused by the buildup of immunoglobulin light chains. Now, an AI-powered platform can detect cardiac amyloidosis by analyzing echocardiograms and using just one commonly acquired ultrasound view of the heart.

The platform, EchoGo Amyloidosis, from Ultromics (Oxford, UK) utilizes AI technology to address the unmet need for early diagnosis of amyloidosis patients, who might otherwise remain undiagnosed until the disease has progressed, delaying treatment and negatively affecting patient outcomes. Developed in collaboration with multiple leading clinical partners, EchoGo Amyloidosis is designed as a module within Ultromics' EchoGo Platform and has received FDA Breakthrough Device Status. This FDA Breakthrough Device Designation represents a significant advancement for amyloidosis patients, who face a bleak five-year mortality rate of 44%-65% after diagnosis if the condition is not detected early enough.

"Receiving a breakthrough designation for EchoGo Amyloidosis, emphasizes the importance of this innovation," said Dr Ross Upton, CEO and Founder of Ultromics. "This is our second breakthrough designation and brings us one step closer to achieving our goal of providing earlier and more accurate diagnosis for this debilitating, underdiagnosed disease. We are excited to continue working with our partners to bring this technology to market and help improve outcomes for patients."

Related Links:

Gold Supplier
Portable X-Ray System
FDR Xair
Gonadal Diaper
Multipurpose Radiography System
NeuVision 460
Densitometry & Data Management Solution
QuickScan Touch Plus

Print article
FIME - Informa



view channel
Image: BiOI ruby-like crystals can improve medical imaging safety by lowering intensities of harmful X-rays (Photo courtesy of University of Cambridge)

Sustainable Solar Cell Material Could Revolutionize Medical Imaging

The use of X-rays for internal body imaging has dramatically changed non-invasive medical diagnostics. Yet, the high dose of X-rays required for these imaging techniques, due to the poor performance of... Read more


view channel
Image: Ezra Flash AI has received 510(k) FDA clearance, enabling roll out of the world’s first 30-minute full body MRI (Photo courtesy of Ezra)

World's First 30 Minute Full Body MRI Scan Offers Fast, Accurate and Affordable Cancer Diagnosis

A cutting-edge artificial intelligence (AI) solution enhances MR image quality, paving the way for a reduction in scan time and consequently, the cost of MRI procedures. This innovation now makes it feasible... Read more

Nuclear Medicine

view channel
Image: New imaging method offers potential for diagnosing, staging, and treating multiple types of cancer (Photo courtesy of SNMMI)

New Imaging Method Superior for Diagnosing Multiple Types of Cancer

Cancer-associated fibroblasts play a significant role in tumor development, migration, and progression. A subset of these fibroblasts expresses fibroblast activation protein (FAP), a protein prominently... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: The global AI-enabled medical imaging solutions market is expected to reach USD 18.36 billion in 2032 (Photo courtesy of Freepik)

Global AI-Enabled Medical Imaging Solutions Market Driven by Need for Early Disease Detection

The AI-enabled medical imaging solutions market is currently in its developmental stages, following the significant role of AI-based tools in combating the COVID-19 pandemic. The pandemic saw an upswing... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.